76.8 F
New York
Saturday, July 2, 2022

Why Enlivex [NASDAQ: ENLV] Shares Skyrocketing Today?

Must read

Shares of Enlivex Therapeutics Ltd. [NASDAQ: ENLV] skyrocketed 15.04% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments of the investors after the firm disclosed that it has got ab green signal to commence a Phase 2b clinical trial for its cure of severe and critical COVID-19 sufferers with the acute respiratory distressed syndrome (ARDS).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

The Phase IIb trial is anticipated to hire more than 152 acute or critical COVID-19 sufferers in clinical centers in Israel and certain European countries. Moreover, it is intended to evaluate the safety and efficacy of AllocetraTM when directed in addition to standard of care medication.

Enlivex Therapeutics Ltd. [NASDAQ: ENLV] shares were trading up 15.04% as the firm has gained +1.52 at the time of writing on Monday. Enlivex Therapeutics Ltd.’s share price went from a low point around $4.49 to briefly over $29.40 in the past 52 weeks, though shares have since pulled back to $12.17. ENLV’s market cap has remained high, reaching $193.94 million at the time of writing.

Furthermore, the scheduled Phase IIb clinical trial will have two primary endpoints. One is ventilation-free survival and another one is recovery for each of the two sub-populations of sufferers in the study. Additionally, the experiment will evaluate several secondary endpoints, including assessment of long-COVID-19 symptoms.

Moreover, Enlivex earlier described positive top-line results from Phase Ib and Phase II investigator-initiated clinical tests of AllocetraTM in COVID-19 sufferers in serious and critical conditions.

More articles

Latest article

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam